{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:07:41Z","timestamp":1780646861477,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T00:00:00Z","timestamp":1429056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1053\/j.ajkd.2015.03.036","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T06:58:14Z","timestamp":1432191494000},"page":"962-971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis"],"prefix":"10.1053","volume":"66","clinical-trial-number":[{"clinical-trial-number":"nct01020487","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01382212","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01447368","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01651000","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01672047","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01696279","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01785875","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Suetonia C.","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Teixeira-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Saglimbene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Macaskill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"de Berardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella","family":"Ruospo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni F.M.","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2015.03.036_bib1","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2015.03.036_bib2","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"8","author":"Block","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1053\/j.ajkd.2015.03.036_bib3","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"issue":"10","key":"10.1053\/j.ajkd.2015.03.036_bib4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1053\/j.ajkd.2015.03.036_bib5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2015.03.036_bib6","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"113","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2015.03.036_bib7","unstructured":"National Health Service England and Wales. Electronic drug\u00a0tariff. http:\/\/www.ppa.org.uk\/edt\/July_2014\/mindex.htm. Accessed July 23,\u00a02014."},{"key":"10.1053\/j.ajkd.2015.03.036_bib8","unstructured":"US Food and Drug Administration. Drug Approval Package: Renagel (sevelamer hydrochloride) capsules. Application no.: 020-926. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/020926.cfm. Accessed July 23,\u00a02014."},{"issue":"1 suppl 1","key":"10.1053\/j.ajkd.2015.03.036_bib9","first-page":"e1","article-title":"US Renal Data System 2013 annual data report","volume":"63","author":"Collins","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2015.03.036_bib10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.ajkd.2009.06.004","article-title":"Benefits and harms of phosphate binders in CKD: A systematic review of randomized controlled trials","volume":"54","author":"Navaneethan","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2015.03.036_bib11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: vitamin D compounds in chronic kidney disease","volume":"147","author":"Palmer","year":"2007","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1053\/j.ajkd.2015.03.036_bib12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jama.2011.308","article-title":"Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis","volume":"305","author":"Palmer","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.ajkd.2015.03.036_bib13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2015.03.036_bib14","first-page":"CD005015","article-title":"Interventions for preventing bone disease in kidney transplant recipients","volume":"2","author":"Palmer","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ajkd.2015.03.036_bib15","first-page":"CD006254","article-title":"Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients","volume":"4","author":"Strippoli","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ajkd.2015.03.036_bib16","first-page":"CD008175","article-title":"Vitamin D compounds for people with chronic kidney disease not requiring dialysis","volume":"4","author":"Palmer","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ajkd.2015.03.036_bib17","first-page":"CD005633","article-title":"Vitamin D compounds for people with chronic kidney disease requiring dialysis","volume":"4","author":"Palmer","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ajkd.2015.03.036_bib18","first-page":"CD006023","article-title":"Phosphate binders for preventing and treating bone disease in chronic kidney disease patients","volume":"2","author":"Navaneethan","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ajkd.2015.03.036_bib19","unstructured":"Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org."},{"issue":"1","key":"10.1053\/j.ajkd.2015.03.036_bib20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/biostatistics\/kxm023","article-title":"An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown","volume":"9","author":"Riley","year":"2008","journal-title":"Biostatistics"},{"issue":"4","key":"10.1053\/j.ajkd.2015.03.036_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/096228029600500402","article-title":"Markov chain Monte Carlo methods in biostatistics","volume":"5","author":"Gelman","year":"1996","journal-title":"Stat Methods Med Res"},{"issue":"7166","key":"10.1053\/j.ajkd.2015.03.036_bib22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/bmj.317.7166.1151","article-title":"Bayesians and frequentists","volume":"317","author":"Bland","year":"1998","journal-title":"BMJ"},{"issue":"4","key":"10.1053\/j.ajkd.2015.03.036_bib23","first-page":"c273","article-title":"Phosphate binder impact on bone remodeling and coronary calcification\u2014results from the BRiC study","volume":"110","author":"Barreto","year":"2008","journal-title":"Nephron"},{"issue":"4","key":"10.1053\/j.ajkd.2015.03.036_bib24","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to haemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2015.03.036_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","article-title":"Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis","volume":"46","author":"Charytan","year":"2005","journal-title":"Am J\u00a0Kidney Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2015.03.036_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1440-1797.2011.01509.x","article-title":"Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: a 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride","volume":"16","author":"Chen","year":"2011","journal-title":"Nephrology"},{"issue":"1","key":"10.1053\/j.ajkd.2015.03.036_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2015.03.036_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2008.09.021","article-title":"A\u00a0randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis","volume":"53","author":"Chonchol","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2015.03.036_bib29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","article-title":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4","volume":"43","author":"Coburn","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2015.03.036_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2015.03.036_bib31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1744-9987.2011.00994.x","article-title":"Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients","volume":"15","author":"El-Shafey","year":"2011","journal-title":"Ther Apher Dial"},{"issue":"1","key":"10.1053\/j.ajkd.2015.03.036_bib32","first-page":"39","article-title":"Prevention of radiologically obvious hyperparathyroidism in dialyses patients by i.v. 1alphaOH vitamin D3 (Etalpha) in association with Mg(OH)2 as sole\u00a0phosphate binder","volume":"22","author":"Fournier","year":"1993","journal-title":"Nieren Hochdruckkrankheiten"},{"issue":"7","key":"10.1053\/j.ajkd.2015.03.036_bib33","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1681\/ASN.V1271530","article-title":"Effect of ibandronate on bone loss and renal function after kidney transplantation","volume":"12","author":"Grotz","year":"2001","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2015.03.036_bib34","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/00007890-199810270-00007","article-title":"Treatment of osteopenia and osteoporosis after kidney transplantation","volume":"66","author":"Grotz","year":"1998","journal-title":"Transplantation"},{"issue":"8","key":"10.1053\/j.ajkd.2015.03.036_bib35","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/ndt\/gfh329","article-title":"Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in\u00a0patients on chronic haemodialysis: a randomized prospective multicentre trial","volume":"19","author":"Hayashi","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1053\/j.ajkd.2015.03.036_bib36","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2015.03.036_bib37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an\u00a0oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.03.036_bib38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5414\/CNP69269","article-title":"An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism","volume":"69","author":"Malluche","year":"2008","journal-title":"Clin Nephrol"},{"issue":"6280","key":"10.1053\/j.ajkd.2015.03.036_bib39","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1136\/bmj.282.6280.1919","article-title":"Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis","volume":"282","author":"Memmos","year":"1981","journal-title":"BMJ"},{"issue":"1","key":"10.1053\/j.ajkd.2015.03.036_bib40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism","volume":"3","author":"Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.03.036_bib41","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/ajkd.2001.27697","article-title":"A\u00a0placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol","volume":"38","author":"Moe","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2015.03.036_bib42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/8756-3282(93)90238-6","article-title":"24,25-Dihydroxy vitamin D3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients","volume":"14","author":"Mortensen","year":"1993","journal-title":"Bone"},{"issue":"4","key":"10.1053\/j.ajkd.2015.03.036_bib43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000188515","article-title":"Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure","volume":"69","author":"Przedlacki","year":"1995","journal-title":"Nephron"},{"issue":"6","key":"10.1053\/j.ajkd.2015.03.036_bib44","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A\u00a01-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in haemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2015.03.036_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2369-12-9","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease","volume":"12","author":"Qunibi","year":"2011","journal-title":"BMC Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2015.03.036_bib46","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ndt\/18.3.582","article-title":"Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study","volume":"18","author":"Sadek","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1053\/j.ajkd.2015.03.036_bib47","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1111\/j.1600-6143.2012.04233.x","article-title":"A\u00a01-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation","volume":"12","author":"Smerud","year":"2012","journal-title":"Am J\u00a0Transplant"},{"issue":"8","key":"10.1053\/j.ajkd.2015.03.036_bib48","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","article-title":"Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up","volume":"21","author":"Spasovski","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1053\/j.ajkd.2015.03.036_bib49","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2015.03.036_bib50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/nep.12029","article-title":"Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism","volume":"18","author":"Ong","year":"2013","journal-title":"Nephrology"},{"issue":"5","key":"10.1053\/j.ajkd.2015.03.036_bib51","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/ndt\/gfs568","article-title":"Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism","volume":"28","author":"Urena-Torres","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2015.03.036_bib52","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.ajkd.2014.04.020","article-title":"Biochemical parameters after cholecalciferol repletion in hemodialysis: results from the VitaDial randomized trial","volume":"64","author":"Massart","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2015.03.036_bib53","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2215\/CJN.05170513","article-title":"Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD","volume":"9","author":"Yokoyama","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2015.03.036_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1681\/ASN.2007080854","article-title":"Mechanisms of vascular calcification in chronic kidney disease","volume":"19","author":"Moe","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9559","key":"10.1053\/j.ajkd.2015.03.036_bib55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0140-6736(07)60194-9","article-title":"Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis","volume":"369","author":"Phrommintikul","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1053\/j.ajkd.2015.03.036_bib56","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate end points in clinical trials: are we being misled?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann Intern Med"},{"issue":"9900","key":"10.1053\/j.ajkd.2015.03.036_bib57","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ajkd.2015.03.036_bib58","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.ackd.2006.10.001","article-title":"The prevalence of symptoms in end-stage renal disease: a systematic review","volume":"14","author":"Murtagh","year":"2007","journal-title":"Adv Chronic Kidney Dis"},{"issue":"10","key":"10.1053\/j.ajkd.2015.03.036_bib59","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1093\/ndt\/gfn207","article-title":"Patients' priorities for health research: focus group study of patients with chronic kidney disease","volume":"23","author":"Tong","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2015.03.036_bib60","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2215\/CJN.01610214","article-title":"Setting research priorities for patients on or nearing dialysis","volume":"9","author":"Manns","year":"2014","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615006332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615006332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:39:07Z","timestamp":1759459147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638615006332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0272638615006332"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.03.036","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.03.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}